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A B S T R A C T
Purpose: A novel vagus nerve stimulation (VNS) device was recently approved in Europe which rapidly
detects increases in heart rates (HR) and applies an additional stimulus if HR-increases exceed a given
threshold. The effects of HR-triggered VNS-pulses on seizures were not reported yet under controlled
conditions. Here, we quantiﬁed the effects of HR-triggered VNS-pulses on the seizure duration in one
patient.
Methods: The novel VNS device was implanted in a 29-year old man with refractory epilepsy. After
implantation, the patient underwent video-EEG telemetry for 68 h with no changes in anticonvulsant
drugs. On the ﬁrst day the patient only received sham-stimulation. During the following 46 h HR-related
VNS-stimulation was set to 2 mA. Seizure duration was determined based on clinical signs.
Results: Twelve stereotypical seizures were recorded (six during sham- and six during the active
stimulation). The VNS device recognised a total of 139 events as a seizure and correctly identiﬁed 11
seizures. The HR-triggered VNS-stimulation signiﬁcantly reduced the total seizure duration from
33.2  4.8 s to 26.5  5 s and the remaining seizure duration after the onset of the extra-stimulation from
27.8  4.3 s to 16.2  3.2 s. With the given conﬁguration in this patient, sensitivity and speciﬁcity of HR-
based seizure-detection amounted to 92% and 13.5%, respectively.
Conclusions: This case illustrates that VNS-stimulation in response to seizure-related HR-increases is
able to signiﬁcantly reduce seizure duration. Despite the limitations of our case, its promising results
should prompt larger studies to conﬁrm the clinical beneﬁt of this novel device.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Vagus nerve stimulation (VNS) is an established and safe
therapy for people with refractory epilepsy leading to a signiﬁcant
improvement of seizure control in a considerable proportion of the
implanted patients [1–3]. A novel VNS device was recently
approved in Europe, which rapidly detects increases in heart rates
(HR) and applies an additional stimulus if the HR-increase exceeds
a given threshold (AspireSRTM generator, Cyberonics Inc., Houston,
USA). Given that the majority of focal seizures are associated with
an increase in HR and only a minority with no apparent change or a
decrease in HR [4–6], many patients could potentially beneﬁt from
the use of this novel device. Importantly, some patients and
relatives have reported an attenuation or shortening of seizures* Corresponding author. Tel.: +49 228 287 14778; fax: +49 228 287 14328.
E-mail address: rainer.surges@ukb.uni-bonn.de (R. Surges).
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however, the effects of such HR-triggered VNS-pulses on the
duration and severity of seizures have not been studied under
controlled conditions. Here we report on a patient with refractory
epilepsy who was recently implanted with such a novel VNS device
at our centre.
2. Methods
2.1. Heart rate device setting
Pre-surgical electrocardiogram (ECG; Schiller, Ottobrunn,
Germany) was performed 24 h before surgery following the
manufacturer’s protocol for the AspireSRTM generator (Cyberonics
Inc., Houston, USA) in order to determine the patient’s heart vector
in seven different body positions. To increase the HR-detection
sensitivity, at least four representative R-waves were measured
from peak to peak in each body position and the R-wave with theserved.
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protocol, a median of 0.8 mV determined of the seven minimum R-
waves was used for the HR detection setting and the third
sensitivity level was applied when R-wave amplitudes were
measured between 0.71 and 0.85 mV. During the entire video-EEG
monitoring, the VNS-detection device was switched on and the
threshold kept unchanged in all conditions. The heart beat
sensitivity threshold of 50% was chosen, because HR increased
by at least 57% during ﬁve habitual seizures recorded during a
diagnostic video-EEG monitoring 2 years prior to VNS-implanta-
tion.
2.2. Video-EEG-monitoring and determination of seizure duration
One day after VNS-implantation, the patient underwent video-
EEG monitoring (Micromed S.p.A, Mogliano Veneto, Italy) with
the help of scalp EEG according to the 10/20 system for 68 h
without changes of anticonvulsant drugs (Fig. 1A). The device
tablet was synchronised with the time of the video-EEG system.
The patient complied with the following procedure: no regular
cyclic VNS-stimuli during the ﬁrst 22 h (control condition). During
this period, the VNS-device only detected HR-increases and
eventually applied a sham-stimulation (stimulus at 0.125 mA
with a pulse width of 500 ms at a frequency of 30 Hz for 60 s). After
these 22 h, cyclic regular VNS-stimulation was initiated up to
2 mA (which was very well tolerated) on days 2–4 (Fig. 1A). The
cardiac-based and seizure-related extra-stimulus was also set to
2 mA. Finally, the patient underwent another 46 h of video-EEG-
monitoring on days 5 and 6 (Fig. 1A). During this phase, the cycle
stimulation was set to 0 mA with a stimulus duration of 7 s, a pulse
width of 500 ms and off-time of 180 min (thus no regular cyclic
VNS stimulation), whereas the HR-triggered VNS-stimulus was
set to 2 mA (stimulus duration 60 s, pulse width 250 ms). Seizure
duration was determined by two epileptologists (KGH, RS) based
on clinical features and blinded to the sham-stimulation period
(control) or active HR-triggered VNS stimulation period (the ictal
EEG pattern was commonly compromised by movement artefacts
and therefore it was less precise to determine seizure duration
based on ictal EEG pattern than on clinical features). TheFig. 1. (A) Flow chart of the VNS-settings at different time points in our patient. (B) Th
condition, n = 6) was compared to the period in which the active HR-related VNS-stimula
duration (after the onset of the VNS-pulse) between the period with sham-stimulation (nremaining seizure duration after the onset of the HR-triggered
VNS-stimulation was measured by subtracting the latency
between seizure onset and start of the HR-triggered VNS-stimulus
from the total seizure duration.
2.3. Statistical measures
The novel VNS-device detects events with HR-increases
exceeding a given threshold and stores date, time and whether
VNS-stimulation was performed in response to the event. Only
those events during which the VNS-device has delivered an extra-
stimulus were considered as a seizure detected by the device.
According to the manufacturer, the device does not stimulate in
the following circumstances: (1) The HR-increase lasts less than
1 s. (2) HR-triggered stimulation was set to 0 mA or seizure
detection was switched off. (3) Seizure detection is switched ‘‘on’’,
but the stimulation is prevented by an internal algorithm (the so-
called ‘‘Enforced-Off-Time’’ which lasts for at least 30 s up to a
duration as long as the HR-triggered stimulation).
The sensitivity of the VNS-device was determined by dividing
the number of correctly detected seizures (true positives as
assessed by video-EEG monitoring) by the sum of the number of
correctly detected seizure and the number of non-detected
seizures (false negatives). The positive predictive value (PPV)
was calculated by dividing the number of true positives by the sum
of the number of true positives and the number of events the
device wrongly classiﬁed as seizures (false positives). The
speciﬁcity was determined by dividing the number of correctly
detected non-seizure events with increased HR (true negatives)
by the number of total non-seizure events with increased HR.
The negative predictive value (NPV) was calculated by dividing the
number of true negatives by the sum of the number of true
negatives and the number of false negatives.
The Shapiro–Wilk test and normal probability plot was used to
test for normality (Rstudio version 0.98.507, FOAS, Boston, USA).
Two-sided unpaired Student’s t-test was performed to compare
seizure duration during sham-stimulation (control condition) and
HR-triggered VNS-stimulation (test condition) (GraphPad Prism 6,
GraphPad Software, San Diego, USA).e total seizure duration in the period with or without sham-stimulation (control
tion was switched on (test condition, n = 6). (C) Comparison of the remaining seizure
 = 5) and active HR-related VNS-stimulation (n = 6). Bar charts represent mean  SD.
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3.1. Case presentation
A 29-years old male patient with refractory epilepsy since early
childhood was referred for presurgical non-invasive assessment.
At admission, he reported having 2–5 focal seizures per 24 h that
usually occurred during sleep. On awakening, he felt a sensory aura
in the left arm followed by bizarre movements. The neurological
and clinical examinations were normal. Magnetic resonance
imaging (MRI) demonstrated a focal cortical dysplasia (FCD) in
the right central region including the pre- and postcentral gyrus
(Fig. 2A and B). Interictal scalp EEG consistently showed spikes and
polyspikes over the central region (Fig. 2C). Video-EEG monitoring
conﬁrmed stereotypical sensory-motor seizures consisting of tonic
contraction of the left limbs followed by hyperkinetic movements,
postures and sometimes unformed vocalisation. The ictal EEG
displayed an arousal pattern followed by generalised EEG
ﬂattening and muscle artefacts, the concomitant one-lead ECG
revealed a prominent HR-increase of 57% or more as compared to
the preictal baseline (mean absolute ictal HR-increase
40  8.2 bpm). Due to the localisation of the lesion in eloquent
areas, resective epilepsy surgery was not recommended. In view of
the prominent ictal HR-increase, we offered the implantation of an
AspireSRTM VNS-device instead. After VNS-implantation, video-EEG
monitoring was performed to evaluate the effects of HR-triggered
VNS-stimulation on seizure properties.
3.2. VNS-based seizure counting
After VNS-implantation, 12 stereotypical seizures with tonic
contraction of the left limbs followed by hyperkinetic movements
and postures were captured. In the control condition, ﬁve seizures
with sham-stimulation and one seizure without sham-stimulation
were recorded. In the test condition, six seizures with active HR-Fig. 2. (A) and (B) MRI revealed a focal cortical dysplasia in the right central region in ax
polyspikes with a central maximum (Cz) in this bipolar transverse montage (scaling 1triggered VNS-stimulation were captured during the video-EEG
monitoring. In 11 of 12 seizures, HR increased by at least 56% as
compared to preictal baseline (mean absolute HR-increase
44.2  9.8 bpm) (simultaneous one-lead ECG could not be analysed
in one seizure due to movements artefacts), which was similar to the
seizures recorded two years prior to VNS-implantation.
The VNS-device detected a total of 160 events of which 21 were
not classiﬁed as seizures (see supplementary Table 1). One of the
21 events was in fact an epileptic seizure with an associated HR-
increase of 78% (conﬁrmed by video-EEG telemetry and simul-
taneous one-lead ECG), which means that 20 events were
correctly identiﬁed as non-seizure related events (speciﬁcity
13.5%, NPV 95.2%). One hundred thirty-nine events were
recognised as a seizure by the VNS-device. Eleven of the 12
seizures were correctly identiﬁed as a seizure, whereas 128 events
were not seizure-related as assessed by video-EEG-monitoring
(sensitivity 92%, PPV 8%).
Supplementary Table 1 related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.seizure.2015.02.
004.
The mean time delay between the clinical seizure onset and
detection by the device was 7.4  5 s. The HR-triggered VNS-
stimulation signiﬁcantly reduced the total seizure duration by 20%
from 33.2  4.8 s to 26.5  5.0 s (p = 0.039, control condition and
test condition n = 6) (Fig. 1B) and the remaining seizure duration
after the onset of the extra-stimulation by 40% from 27.8  4.3 s to
16.2  3.2 s (p = 0.001, control condition n = 5, test condition n = 6)
(Fig. 1C). No seizure was immediately stopped at the onset of HR-
triggered VNS-stimulation. Interestingly, the patient himself also
noticed a reduction of the seizure duration at his last follow-up 3
months after implantation of the VNS-device upon a combination of
cyclic and HR-triggered VNS stimulation. Seizure frequency was also
remarkably reduced, since he reported 2 of 7 days without seizures,
whereas before VNS-implantation, he has suffered from seizures
every day.ial and coronal FLAIR-weighted images. (C) Interictal EEG showed focal spikes and
00 mV, 1 s1).
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Our case illustrates that additional VNS-stimulation in response
to seizure-related HR-increases is able to signiﬁcantly reduce
seizure duration. Furthermore, our data highlights the high
sensitivity, but low speciﬁcity of the novel VNS-device to detect
seizures with associated HR-increases. To the best of our
knowledge, this is the ﬁrst study that evaluated the effect of
seizure-related VNS-pulses on seizure duration in humans under
controlled conditions. In previous studies, the evaluation of effects
of on demand VNS stimulation was restricted to historical controls
or subjective reports given by patients and caregivers about VNS-
stimulation from magnet activation [9]. The few studies that used
EEG recordings as an objective measurement are mostly in the
interictal period [10,11]. In one study, an additional VNS-
stimulation by magnet activation appeared to promptly stop the
ongoing seizure, as captured during a video-EEG-monitoring [12].
In our patient, none of the six seizures was terminated by the HR-
triggered VNS-pulse, but signiﬁcantly shortened. Our ﬁndings
support reports of patient and caregivers about seizure shortening
due to magnet VNS pulses [7,8]. However, some patients are not
able to use the magnet properly and caregivers are not always
around when seizures occur [9]. These patients may potentially
beneﬁt from automatically triggered VNS-stimulation.
The individual conﬁguration of the novel VNS-device in our
patient resulted in a high sensitivity of seizure detection and a high
NPV. In contrast, speciﬁcity and PPV were low. As the HR-threshold
is adaptable, these values are likely to change given individual
circumstances. For example increasing the HR-threshold from 50
to 60% may increase PPV and speciﬁcity, whereas sensitivity and
NPV may decrease (some seizures had an HR-increase below 60%
and might not have been detected). Since these features vary
greatly between individuals, no generalisable conclusions regard-
ing sensitivity, speciﬁcity, PPV and NPV of the device can be drawn
from one patient [13]. This case indicates, however, the difﬁculties
of automatic seizure detection using a single parameter [14]. The
VNS-device has failed to detect one epileptic seizure in our patient,
because it was already activated by a preceding HR-increase
caused by a sleep arousal 107 s before the seizure onset (conﬁrmed
by video-EEG telemetry). Therefore, the VNS-device was unable to
stimulate (Enforced-Off-Time, see Section 2). An alternative
explanation could be that the preceding sleep arousal was in fact
a true epileptic seizure which was terminated by HR-triggered
stimulation. Given the fact that the responsive VNS-stimulation
was applied in average 7.4 s after the clinical seizure-onset,
however, it is rather unlikely that the seizure was terminated
before the onset of typical clinical symptoms. Moreover, the
distribution of the events recorded by the VNS-device showed a
circadian pattern with a peak during night and in the early morning
(see supplementary Fig. 1), suggesting that the detected cardiac
events are most probably due to frequent physiological arousals
during sleep [15].
Supplementary Fig. 1 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.seizure.2015.02.004.
There are two major limitations of our study that need to be
critically discussed. Firstly, the lack of randomisation of VNS
stimulation may impair the validity of our results to some extent.
Randomisation was difﬁcult to realise because of the technical
restrictions of the VNS-device conﬁguration (e.g. it was impossible
to set the device to an alternating one-to-one sham- and active-
stimulation). Therefore, instead of randomisation we controlled for
known confounders (e.g. we kept anticonvulsant drugs unchanged
during the observation period; cyclic VNS-stimulation was not
applied during the video-EEG monitoring). In this context, it is
important to note that we do not know the variability of seizure
duration from day-to-day or after longer time periods. For instancein our patient, the mean seizure duration 2 years prior to VNS-
implantation amounted to about 25 s under the same anticonvul-
sant drug regime, which is shorter than that of the seizures
recorded 1 day after VNS implantation with sham-stimulation. To
estimate the day-to-day variability, we have randomly selected
one patient with frequent hyperkinetic seizures and determined
the seizure duration for several days without signiﬁcant differ-
ences (see supplementary Fig. 2), strengthening our hypothesis of a
VNS-induced shortening of seizure duration. Secondly, we have
analysed data of one patient only. The strength of our study,
however, is the relatively high number of recorded seizures under
video-EEG surveillance, providing the true number and the clinical
features of the epileptic seizures.
Supplementary Fig. 2 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.seizure.2015.02.004.
The exact mechanisms of how VNS exerts its anticonvulsant
effects are still unknown [1,16], but the modulation of cortical
excitability through thalamocortical projections as a result of the
stimulation of the vagus nerve is thought to play a role [17,18]. At
least in the interictal period, however, no apparent effects on EEG
occurred during vagus nerve stimulation [10,11]. One may
speculate that the observed clinical effects on seizures are not
speciﬁc to the simulation of the vagus nerve, but are rather
unspeciﬁc, e.g. due to activation of the arousal system.
In conclusion, our case provides evidence that additional VNS-
stimulation in response to seizure-related HR-increases is able to
signiﬁcantly reduce seizure duration. From a clinical point of view,
a signiﬁcant reduction of seizure duration may protect patients
from the potential harm of prolonged seizures and maybe from
evolution into generalised convulsive seizures [19]. Despite the
limitations of our report, this promising result prompts larger
studies to conﬁrm the clinical beneﬁt of this novel VNS-device.
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